Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE SULFATE versus PAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE SULFATE versus PAMINE.
ATROPINE SULFATE vs PAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine at parasympathetic postganglionic junctions. Increases heart rate, reduces exocrine secretions, relaxes smooth muscle in GI and GU tracts, and dilates pupils.
Antimuscarinic; competitively blocks acetylcholine at muscarinic receptors, reducing smooth muscle spasm and secretions.
0.5 to 1 mg intravenously or intramuscularly every 3 to 5 minutes as needed, up to a total of 3 mg (3 doses) for bradycardia; 0.5 to 1 mg subcutaneously, intramuscularly, or intravenously every 4 to 6 hours for antisecretory effects; 1 to 2 mg intravenously every 5 minutes for organophosphate poisoning.
2.5 mg orally or subcutaneously 30-60 minutes before meals and at bedtime; maximum 10 mg/day.
None Documented
None Documented
Clinical Note
moderateDopamine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dopamine."
Clinical Note
moderateDopamine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dopamine."
Clinical Note
moderateDopamine + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Dopamine."
Clinical Note
moderateDopamine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Dopamine."
Terminal elimination half-life approximately 2-4 hours in adults; prolonged in elderly and infants; clinically significant due to potential accumulation with repeated dosing.
1.5-2 hours, necessitating dosing every 4-6 hours for sustained therapeutic effect.
Renal excretion of unchanged drug and metabolites; ~50% excreted unchanged in urine; remainder as inactive metabolites (tropine, tropic acid); biliary/fecal excretion minor.
Primarily renal (70-80% unchanged), with 20-30% fecal via biliary elimination.
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent